WANY
RVMD icon

Wealthspire Advisors (New York)’s Revolution Medicines RVMD Stock Holding History

Wealthspire Advisors (New York)’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12
Closed -$560 – 2509
2025
Q3 		$560 Buy
+12
New +$470 ﹤0.01% 2819

Other funds holding RVMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wealthspire Advisors (New York)'s RVMD Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Revolution Medicines (RVMD) in Q4 2025, closing a stake of 12 shares — an estimated $560 sold.

Wealthspire Advisors (New York) first reported a position in RVMD in Q3 2025 and held it in 1 quarter. The position peaked at $560 in Q3 2025. 386 funds tracked by Wall St. Rank hold RVMD as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Revolution Medicines position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 12 Revolution Medicines shares in Q4 2025, an estimated $560.
  • Wealthspire Advisors (New York) first reported a position in Revolution Medicines in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Revolution Medicines position peaked at $560 in Q3 2025.
  • 386 funds tracked by Wall St. Rank held Revolution Medicines as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.